Stocks · News reference

Barclays Maintains Underweight Rating on PacBio, Raises Price Target

2026-11-06 14:03:09 UTC

Barclays maintained its Underweight rating on Pacific Biosciences and increased its price target from $1.25 to $2.00.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.ai2026-11-11 14:02:46 UTC
Pacific Biosciences of California, Inc. Announces $100 Million At-the-Market Equity Offering
Pacific Biosciences of California, Inc. has entered into a sales agreement with Allen & Company to sell up to $100 million of its common stock through an at-the-market offering.
PACB
SEC EDGAR2026-11-10 21:07:06 UTCSEC EDGAR
8-K filing — PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
Filed: 2026-11-10 AccNo: 0001104659-26-125166 Size: 603 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
PACB
Benzinga2026-11-09 21:07:53 UTCBenzinga Newsdesk
UBS Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.7
PACB
Fiscal.ai2026-11-09 14:02:07 UTC
UBS Adjusts Price Target on Pacific Biosciences of California
UBS has lowered its price target for Pacific Biosciences of California, Inc. while maintaining a Neutral rating on the stock.
PACB
Fiscal.ai2026-11-06 14:03:09 UTC
PacBio Reports Third-Quarter 2026 Financial Results and Restructuring
PacBio reported its third-quarter 2026 financial results, showing a 6% year-over-year revenue increase and a workforce reduction of approximately 8%.
PACB
Fiscal.ai2026-11-06 14:03:09 UTC
Piper Sandler Maintains Neutral Rating on PacBio, Raises Price Target
Piper Sandler maintained its Neutral rating on Pacific Biosciences and increased its price target from $2.00 to $3.00.
PACB